On July 8, 2012, the Centers for Medicare & Medicaid Services (CMS) released two major Medicare proposed rules impacting payment for physician and hospital outpatient services in 2014. ASH will submit comments to CMS on the proposed rules by the September 6 deadline and would like to incorporate feedback from the Society's practice-based members.
On July 8, 2012, the Centers for Medicare & Medicaid Services (CMS) released two major Medicare proposed rules impacting payment for physician and hospital outpatient services in 2014. ASH will submit comments to CMS on the proposed rules by the September 6 deadline and would like to incorporate feedback from the Society's practice-based members. Review ASH's detailed analysis of the key issues and potential impact that the proposed rules will have on hematology and please contact ASH Government Relations and Practice Manager Stephanie Kaplan by August 16 with any comments you have about the proposed rule.
ASH Analysis of the Proposed Medicare Physician Fee Schedule (MPFS) CMS is proposing several changes to the physician fee schedule that will result in a net overall reduction in payment of 1 percent for hematology-oncology services. Modest changes are proposed for office-based evaluation and management (E/M) services while hospital visit and critical care codes will see increases of about 3 percent. Reductions are proposed for infusion codes, bone marrow biopsy and aspiration procedures. As in past years, the MPFS rule does not address the Sustainable Growth Rate formula driven payment reductions that will occur unless Congress takes action before the end of the year.
Read the full story here: http://bit.ly/17owDI6
Source: ASH
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Overcoming CAR T Manufacturing Failure in LBCL
March 21st 2025Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Read More